Back to announcement
20250423_OMED_Laporan Informasi dan Fakta Material_31877447_lamp2.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 3
Page 1
INVESTOR BULLETIN COMPANY OVERVIEW
OPERATION UPDATE FY2024 PT Jayamas Medica Industri Tbk (OMED), established
April 23rd 2025 in the early 2000s, has grown into a leading player in
Indonesia’s medical equipment and supplies industry.
Share Price Data (per 22th of April 2025): OMED’s extensive product portfolio includes approximately
6,000 active SKUs, supported by a comprehensive
Ticker on IDX OMED
distribution network that reaches 514 cities across all 34
Last Closing Price (IDR): 156 provinces in Indonesia.
Outstanding Shares: 27.058.850.000
COMPANY HIGHLIGHTS
Market Cap (IDR Bn): 4.221
• PT Jayamas Medica Industri Tbk (OMED) delivered
robust financial results in FY2024, underscoring its
Shareholder Structure: strong position in Indonesia’s healthcare manufacturing
industry. The company recorded revenue of IDR 1.89
PT Intisumber Hasilsempurna (%): 83,30
trillion, marking an 8.6% year-on-year (YoY) growth,
Yacobus Jemmy Hartanto (%): 0,89 supported by outstanding performance in Wound Care
(+25.1%), Diagnostic & Equipment (+19.4%), and
Siane Soetanto (%): 0,89 Walking Aids & Rehabilitation (+16.4%). This solid topline
Public (%): 14,92 growth reflects OMED’s strategic alignment with evolving
domestic healthcare demands.
• OMED's profitability also surged, with EBITDA
Contact us:
margin expanding to 21.6% and net profit climbing
Corporate Secretary & Investor Relation 24.3% YoY to IDR 324.0 billion with a margin of 17.2%.
This impressive performance reflects the company's
Phone: +62 811-3075-8028 operational efficiency and implemented cost management
Email: strategies.
corporate.secretary@onemed.co.id
ir@onemed.co.id • Operationally, OMED increased production volume
by 5.6% to 2.54 billion units and demonstrated strong
Website: pricing power, notably with a 45.5% price hike in hospital
www.onemed.co.id furniture, while effectively passing on USD-denominated
cost increases through its institutional-focused pricing
strategy.
Company’s Presence Across Country
Sumatera 1 National Distribution
Center
Kalimantan Sulawesi
23 Branch offices and
warehouses
Maluku
Papua
11 Sales offices
Bali Lombok
Java Flores 28 Omnichannel
Stores
Page 2
Batang Facility Strengthens Supply Chain Capabilities
Batang Facility in Central Java has started
operations successfully, further strengthening our
supply chain capabilities. Spanning 35,650
square meters, the facility is dedicated to
gauze production with an impressive capacity
of 2 million square meters. The facility
reflects our commitment to quality and
efficiency, while serving as a key asset in
ensuring a stable and scalable supply of
essential healthcare materials. Looking ahead,
Batang will play a pivotal role in our growth
strategy as we plan to produce OMED wound
care products on-site, supporting our broader
mission to expand in the healthcare sector and
enhance patient outcomes across the region.
India Partnership Gains Traction in Urology Expansion
OMED recent strategic partnership with an Indian company to localize urology
products is progressing on track. Cleanroom construction (Class 10,000) has
been completed, while equipment installation and staff training are currently
underway. Product registration is in process, with sales launch targeted
for Q3 2025. This initiative is expected to contribute IDR 15 billion in
revenue, marking a key milestone in our international growth strategy and
strengthening our position in the regional healthcare market.
OMED’s Domestic Focus Strengthens Resilience Amid
Tariff Pressures
OMED’s deeply rooted domestic focus—generating
99.8% of its revenue within Indonesia—offers strong
insulation from global trade volatility, ensuring that even amidst
external shocks like the recently imposed 32% U.S. reciprocal
tariff, the company remains largely unaffected due to its minimal
0.2% export exposure, while the Indonesian government’s 90-
day tariff suspension starting April 5, 2025, further strengthens
this defensive positioning by providing a buffer against near-
term disruptions and reinforcing investor confidence in its stable
revenue base.
With over IDR 1.2 trillion in cash, zero debt, and
consistently strong free cash flow, OMED is strategically
equipped to capture the momentum of Indonesia’s expanding
healthcare investments through a high-margin, locally anchored
business model that enables both operational agility and long-
term sustainability, as the company continues to meet growing
public sector demand and capitalize on national policy support
for medical infrastructure development.
Page 3
Operational Highlights Audited
Production Price
(in thousand units) 2023 2024 YoY (in IDR) 2023 2024 YoY
Sales Volume Average Selling Price
Disposable & Consumables 1,520,193 1,570,265 3.29% Disposable & Consumables 578 586 1.38%
Wound Care 372,237 465,627 25.10% Wound Care 645 617 (4.34%)
Antiseptic & Dialysis Fluid 368,814 378,390 2.60% Antiseptic & Dialysis Fluid 514 546 6.23%
Diagnostic & Equipment 2,134 2,547 19.35% Diagnostic & Equipment 103,068 100,655 (2.34%)
Walking Aids & Rehab 1,449 1,686 16.36% Walking Aids & Rehab 52,320 48,789 (6.75%)
Biotech & Lab 142,140 122,800 (13.61%) Biotech & Lab 694 739 6.48%
Hospital Furniture 84 122,800 (13.61% Hospital Furniture 399,745 581,452 45.46%
Total 2,407,051 2,541,385 5.58%
Financial Highlights
Revenue (In Billion IDR) EBITDA (In Billion IDR) Net Profit (In Billion IDR)
1,886
25.0% 16.8%
20.7% 21.6% 17.2%
14.9%
1,739 1,736
434.9 407.3 324.0
359.5 290.5 260.9
2022 2023 2024 2022 2023 2024 2022 2023 2024
EBITDA EBITDA Margin Net Profit Net Profit Margin
Assets (In Billion IDR) Liabilities (In Billion IDR) Equity (In Billion IDR)
2,826 2,496
2,583 2,245
2,507 2,069
437
338 330
2022 2023 2024 2022 2023 2024 2022 2023 2024
Names mentioned 4 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Intisumber Hasilsempurna
p.1
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.